文献速递脑血管病

癌症患者再灌注治疗的即刻与长期结局

Immediate and Long-Term Outcomes of Reperfusion Therapy in Patients With Cancer.
PubMed 文献 · Stroke · 2021-04-29

基于全国再灌注治疗登记研究,纳入1338例接受再灌注治疗的卒中患者,按癌症活动性分为活动性癌症、非活动性癌症和无癌症史三组。活动性癌症患者24小时神经改善和不良事件与其他组相似,但3个月功能结局较差,6个月生存率更低,活动性癌症独立关联于不良生存。

要点

  • 活动性癌症患者再灌注治疗后24小时神经改善和不良事件与其他组相似。
  • 活动性癌症患者3个月功能结局较差,但36.4%仍达到功能独立。
  • 活动性癌症独立关联于6个月不良生存(HR 3.973,95%CI 2.528–6.245)。

核心结论

  • 活动性癌症患者再灌注治疗的不良事件和短期结局与其他组相似,但长期生存更差。

研究设计与样本

  • 基于全国再灌注治疗登记研究,纳入1338例接受再灌注治疗的卒中患者。
  • 按癌症活动性分为活动性癌症62例(4.6%)、非活动性癌症78例(5.8%)和无癌症史1198例(89.5%)。
  • 969例接受静脉溶栓,685例接受血管内治疗,其中316例接受联合治疗。

主要发现

  • 活动性癌症患者合并症更多且卒中更严重,但24小时神经改善和不良事件(包括脑出血)与其他组相似。
  • 活动性癌症患者3个月功能结局较差,但36.4%达到功能独立。
  • 病因明确的卒中患者中,52.9%尽管有活动性癌症仍达到功能独立。
  • 6个月随访期间,46.6%的活动性癌症患者死亡,活动性癌症独立关联于不良生存(HR 3.973,95%CI 2.528–6.245)。

临床怎么用

  • 活动性癌症不是再灌注治疗的禁忌,短期安全性与无癌症患者相似。
  • 应关注活动性癌症患者长期生存预后,但部分患者仍可从再灌注治疗中获得良好功能结局。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: Patients with acute stroke are often accompanied by comorbidities, such as active cancer. However, adequate treatment guidelines are not available for these patients. The purpose of this study was to evaluate the association between cancer and the outcomes of reperfusion therapy in patients with stroke. METHODS: We compared treatment outcomes in patients who underwent reperfusion therapy, using a nationwide reperfusion therapy registry. We divided the patients into 3 groups according to cancer activity: active cancer, nonactive cancer, and without a history of cancer. We investigated reperfusion processes, 24-hour neurological improvement, adverse events, 3-month functional outcome, and 6-month survival and related factors after reperfusion therapy. RESULTS: Among 1338 patients who underwent reperfusion therapy, 62 patients (4.6%) had active cancer, 78 patients (5.8%) had nonactive cancer, and 1198 patients (89.5%) had no history of cancer. Of the enrolled patients, 969 patients received intravenous thrombolysis and 685 patients underwent endovascular treatment (316 patients received combined therapy). Patients with active cancer had more comorbidities and experienced more severe strokes; however, they showed similar 24-hour neurological improvement and adverse events, including cerebral hemorrhage, compared with the other groups. Although the functional outcome at 3 months was poorer than the other groups, 36.4% of patients with active cancer showed functional independence. Additionally, 52.9% of the patients with determined stroke etiology showed functional independence despite active cancer. During the 6-month follow-up, 46.6% of patients with active cancer died, and active cancer was independently associated with poor survival (hazard ratio, 3.973 [95% CI, 2.528–6.245]). CONCLUSIONS: In patients with active cancer, reperfusion therapy showed similar adverse events and short-term outcomes to that of other groups. While long-term prognosis was worse in the active cancer group than the nonactive cancer groups, not negligible number of patients had good functional outcomes, especially those with determined stroke mechanisms.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Yoo J, Kim YD, Park H, et al. Immediate and Long-Term Outcomes of Reperfusion Therapy in Patients With Cancer. Stroke. 2021. PMID: 33910369. doi:10.1161/STROKEAHA.120.032380

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。